Main Article Content
ume in one second (FEV 1 ) reversibility in newly developed asthma
Methods A cross sectional study was done on 52 patients aged 6-
14 years who were recruited from a longitudinal study of 161 newly
developed asthmatic children. Pre and post-bronchodilator FEV 1
were obtained to calculate the reversibility. Seven patients had to
perform peak expiratory volume (PEV) variability before recruited.
Some variables including sex, age, height, onset of asthma, fre-
quency of asthma attacks at the time of the test were analyzed to
evaluate their roles in the outcome of FEV 1 reversibility using paired
sample t-test, Pearson’s correlation coefficient, and multi regres-
Results Mean pre- and post-bronchodilator FEV 1 were 1.14 (SD
0.24) and 1.31 (SD 0.28), respectively. FEV 1 reversibility ranged
between 6%-36%. Bivariate analyses demonstrated significant cor-
relation between either cough (p=0.031) or symptom-free (p=0.041)
and the airway reversibility. Multivariate analysis showed that cough
was an important factor influencing airway reversibility (p=0.0246).
Conclusion Cough is an important influencing factor of the air-
Authors who publish with this journal agree to the following terms:
Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
atrics. Philadelphia: WB Saunders Co; 1996. p. 628-40.
2. Bierman CW, Pearlman DS. Asthma. In: Kendig EL,
Chernick V, editors. Disorders of respiratory tract in chil-
dren. Philadelphia: WB Saunders Co; 1990. p. 557-96.
3. Wenzel SE, Larsen GL. Assessment of lung function:
pulmonary function testing. In: Bierman, editor. Al-
lergy, asthma, and immunology from infancy to adult-
hood. 3 rd ed. Philadelphia: WB Saunders Co; 1996. p.
4. Weiss ST. Asthma epidemiology: risk factors and natu-
ral history. In: Bierman, editor. Allergy, asthma, and
immunology from infancy to adulthood. 3 rd ed. Phila-
delphia: WB Saunders Co; 1996. p. 472-81.
5. Dinwiddie R. Diagnosis and management of pediatric
respiratory disease. New York: Churchill Livingatone
Inc; 1997. p. 167-93.
6. Kanner RE. Spirometry in children. Methodology for
obtaining optimal result for clinical and epidemiologic
studies. Am Rev Respir Dis 1983;127:720-4.
7. Pfaff JK, Morgan WJ. Pulmonary function in infants
and children. Pediatr Clin North. Am 1984;9:402-22.
8. Enright PL, Lebowitz, Cockroft DW. Physiologic mea-
sures: pulmonary function tests. Asthma outcome. Am
J Respir Crit Care Med 1994;149(2Pt2):9-18.
9. Haddad GG, Fontan JJP. Respiratory function and ap-
proach to respiratory disease. In: Nelson WE, editor.
Textbook of pediatrics. 15 th ed. Philadelphia: WB
Saunders Co; 1996. p. 1170-85.
10. Godfrey S. Functional differences between the lungs
of normal and asthmatic children. In: Tinkelman DG,
Falliers CJ, Naspitz CK, editors. Childhood asthma
pathophysiology and treatment. New York: Marcel
Dekker Inc; 1987. p. 1-20.
11. Shapiro GG, Bierman CW. Presentation of asthma in chil-
dren: differential diagnosis. In: Tinkelman DG, Falliers CJ,
Naspilz CK. Childhood asthma pathophysiology and treat-
ment. New York: Marcel Dekker Inc; 1987. p. 203-26.
12. Bone RG. Goals of asthma management. A step care
approach. Chest 1996;109:1056-65.
13. Pare PD, Lawson LM, Brooks LA. Pattern of response
to inhaled bronchodilators in asthmatic. Am Rev
Respir Dis 1983;127:680-5.
14. Selroos O. Lofroos AB, Pietinalho A, Riska H. Compari-
son of terbutaline and placebo from a pressurised me-
tered dose inhaler and a dry powder inhaler in a subgroup
of patients with asthma. Thorax 1994:49:1228-30.
15. Zureik M, Liard R, Segala C, Henry C, Korobaeff M,
Neukirch F. Peak expiratory flow rate variability in
population surveys. Does the number of assessments
matter? Chest 1995;107:418-23.
16. Gautrin D. Comparison between peak expiratory flow rates
(PEFR) and FEV 1 in the monitoring of asthmatic subjects
at an outpatient clinic. Chest 1994;106:1419-260.
17. Pearlman DS, Lemanske RF Jr. Asthma (bronchial
asthma): principles of diagnosis and treatment. In:
Bierman, editor. Allergy, asthma, and immunology from
infancy to adulthood. 3 rd ed. Philadelphia: WB
Saunders Co; 1996. p. 484-96.
18. McBride JT, Wohl ME. Pulmonary function tests.
Pediatr Clin North Am 1979;26:537-51.
19. Neijens HJ, Duiverman EJ, Kerrebijn KF. Bronchial re-
sponsiveness in children. Pediatr Clin North Am